Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Long-Term Safety of Pirfenidone in Idiopathic Pulmonary Fibrosis Patients Completing CAPACITY
2007-007800-13Phase 3Completed
- Sponsor
- InterMune
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by InterMune. Primary endpoint: Long-term safety of pirfenidone 2403 mg/day. Started Feb 2008; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2007-007800-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007800-13.